Testing effectiveness (Phase 2)Ended earlyNCT03568071
What this trial is testing
Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
Who this might be right for
Atopic Dermatitis
Lakefront Biotherapeutics NV 207